{"schema_version":"secwatch.filing_event.v1","accession":"0001297184-24-000004","form_type":"8-K","ticker":"AMPH","cik":"0001297184","company_name":"Amphastar Pharmaceuticals, Inc.","filed_at":"2024-02-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:23.707315+00:00","generated_at":"2026-06-05T08:20:44.804514+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Amphastar Q4 net revenue $178.1M, GAAP EPS $0.68; FY revenue $644.4M","bullets":["Q4 2023 net revenue $178.1M (+32% YoY); GAAP net income $36.2M ($0.68 EPS).","Adjusted non-GAAP Q4 net income $46.9M ($0.88 EPS) vs $37.6M ($0.73 EPS) in Q4 2022.","Full-year net revenue $644.4M (+29% YoY); GAAP net income $137.5M ($2.60 EPS).","Full-year adjusted non-GAAP net income $175.7M ($3.32 EPS) vs $103.2M ($1.97 EPS) in FY2022.","CEO cited strong performance of glucagon, Primatene MIST, BAQSIMI acquisition, and BLA submission for Insulin Aspart."],"urls":{"canonical":"https://secwatch.observer/filing/0001297184-24-000004","json":"https://secwatch.observer/filing/0001297184-24-000004.json","markdown":"https://secwatch.observer/filing/0001297184-24-000004.md","text":"https://secwatch.observer/filing/0001297184-24-000004.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1297184/000129718424000004/0001297184-24-000004-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1297184/000129718424000004/amph-20240228x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T08:20:44.804514+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}